HOME >> BIOLOGY >> NEWS
New egg-free flu vaccine called promising for those with egg allergy

SAN DIEGO, April 2 - Austrian researchers have developed a unique flu vaccine that is made without egg proteins, which can trigger rare but potentially fatal allergic reactions in some people. "The development represents the newest and most successful approach to influenza vaccine development in 50 years," says Otfried Kistner, Ph.D.

Kistner, a virologist with Baxter Hyland Immuno in Orth/Donau, Austria, and director of the research project, described the vaccine today at the 221st national meeting of the American Chemical Society, the world's largest scientific society.

Although at least two other manufacturers are testing egg-free flu vaccines, Kistner notes that only his company is using cells that have previously been accepted by regulatory authorities in the United States and Europe for human vaccine production.

According to the Austrian scientists, their new manufacturing technique is faster than methods that require chicken eggs, which can be in short supply during a large outbreak. As a result, the technique is expected to lessen the likelihood of flu vaccine shortages like those in the United States last year.

Phase I, II and III clinical trials were done in the United Kingdom, Austria and Poland with more than 2,500 volunteers. They were divided into two age groups: 18-59, and 60 and above. The studies showed that the new vaccine was effective in inducing specific antibodies against influenza, an indication that the vaccine will protect against infection.

"This does not mean that (conventional) vaccines are bad," says Kistner. "The benefit of vaccination is much greater than the risk of allergic reaction. The point of our vaccine is to improve it and minimize the risks which may appear."

Among the older patients who received the new vaccine, significantly fewer adverse effects were observed compared to those who received conventional vaccines. In the younger group, no significant differ
'"/>

Contact: Charmayne Marsh
202-872-4445
American Chemical Society
25-Mar-2001


Page: 1 2 3

Related biology news :

1. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
2. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows
3. UC Irvine scientists to develop vaccine to combat bioterrorism threat from deadly bacteria
4. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
5. Protective gene may enhance vaccine responses
6. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
7. New glycan arrays discover autoimmunogenic activities of SARS-CoV: concern over monkey vaccine
8. Growing new breed of vaccine-producing plants to fight human diseases worldwide
9. Childrens Hospital Boston receives more than $10 million to help make smallpox vaccine safer
10. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
11. Herpes tool allows researchers to customize Alzheimers vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
Breaking Biology Technology:
Cached News: